1 Menzel C, "rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I" 44 : 1065-1068, 2003
2 Ronga G, "Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma" 26 : 1448-1452, 1999
3 Giovanella L, "Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures" 44 : 648-652, 2006
4 Torrens J, "Serum thyroglobulin measurement: Utility in clinical practice" 30 : 1-34, 2001
5 Tuttle RM, "Recombinant-human TSH-assisted radioactive iodine remnant ablation achieves short term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal" 49 : 764-770, 2008
6 Cramp WA, "Recent developments in the radiobiology of cellular membranes" 33 : 945-952, 1994
7 Sweeney DC, "Radioiodine therapy for thyroid cancer" 24 : 803-839, 1995
8 Pacini F, "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study" 91 : 926-932, 2006
9 Crevenna R, "Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxin supplementation therapy" 11 : 597-603, 2003
10 Dow KH, "Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy" 7 : 613-619, 1997
1 Menzel C, "rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I" 44 : 1065-1068, 2003
2 Ronga G, "Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma" 26 : 1448-1452, 1999
3 Giovanella L, "Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures" 44 : 648-652, 2006
4 Torrens J, "Serum thyroglobulin measurement: Utility in clinical practice" 30 : 1-34, 2001
5 Tuttle RM, "Recombinant-human TSH-assisted radioactive iodine remnant ablation achieves short term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal" 49 : 764-770, 2008
6 Cramp WA, "Recent developments in the radiobiology of cellular membranes" 33 : 945-952, 1994
7 Sweeney DC, "Radioiodine therapy for thyroid cancer" 24 : 803-839, 1995
8 Pacini F, "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study" 91 : 926-932, 2006
9 Crevenna R, "Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxin supplementation therapy" 11 : 597-603, 2003
10 Dow KH, "Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy" 7 : 613-619, 1997
11 Botella-Carretero JI, "Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma" 10 : 601-610, 2003
12 Lima N, "Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer" 25 : 110-115, 2002
13 Bernier MO, "Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer" 32 : 1418-1421, 2005
14 Lee HJ, "Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation 131I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma" 30 : 63-68, 2007
15 Toubeau M, "Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy in patients with differentiated thyroid cancer" 45 : 988-994, 2004
16 Arslan N, "Post-surgical ablation of thyroid remnants with high-dose 131I in patients with differentiated thyroid carcinoma" 22 : 1021-1027, 2001
17 Sugino K, "Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH" 53 : 723-728, 2006
18 Karam M, "Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates" 24 : 489-495, 2003
19 Luster M, "Guidelines for radioiodine therapy of differentiated thyroid cancer" 35 : 1941-1959, 2008
20 Schlumberger M, "Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice" 151 : 539-548, 2004
21 Rosario PW, "Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 <1 ng/ml determined by traditional assays?" 68 : 338-342, 2008
22 Sawka AM, "Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer" 89 : 3668-3676, 2004
23 Robbins RJ, "Clinical review 156: recombinant human thyrotropin and thyroid cancer management" 88 : 1933-1938, 2003
24 Mazzaferri EL, "Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer" 86 : 1447-1463, 2001
25 Mazzaferri EL, "An overview of the management of papillary and follicular thyroid carcinoma" 9 : 421-427, 1999
26 Schroeder PR, "A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal" 91 : 878-894, 2006